Larvol Delta - Afbody-and-Inmagene-announce-First-Patient-Dosed-in-the-Global-Phase-2-ASPIRE-Trial-of-izokibep-for-patients-with-active-Ankylosing-Spondylitis

izokibep (ABY-035) - Affibody

https://www.affibody.se/affibody-and-inmagene-announce-first-patient-dosed-in-the-global-phase-2-aspire-trial-of-izokibep-for-patients-with-active-ankylosing-spondylitis/

Aug 26, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next